Harvard Bioscience, Inc

Harvard Bioscience designs, manufactures, and sells life-science research tools used in drug discovery, translational medicine, and preclinical testing. Its portfolio spans proprietary instruments, systems, software, and consumables sold to academic labs, pharma/biotech companies, CROs, hospitals, and government research institutions worldwide.

−54,1 %

57,7 %

−65,5 %

−8,1 %

2.20

1.25

— Harvard Bioscience, Inc
%
Preclinical products54% Behavioral, respiratory, organ-based, and surgical systems used in preclinical research and testing.
Cellular and molecular technology33% Instruments and accessories for tissue, cell, and molecular biology workflows.
Third-party distributed products13% Resold instruments, accessories, and consumables from other manufacturers.

The company sells primarily to pharmaceutical and biotechnology companies, universities, hospitals, government...

  • Pharmaceutical and biotechnology companiesprimary

    Buy research and preclinical systems for drug and therapy discovery, screening, and translational studies.

  • Academic institutionsprimary

    Buy instruments and accessories for basic research, physiology, and life-science education.

  • Contract research organizationsprimary

    Buy high-throughput testing and monitoring systems for outsourced preclinical programs.

  • Government laboratoriessecondary

    Buy specialized research platforms for funded biomedical and defense-related studies.

  • Hospitals and medical research centerssecondary

    Buy tools for translational and disease-model research supporting therapy development.

Harvard Bioscience operates in the United States, Europe, and China, selling through both direct and distributor...

  • •Operations in the United States, Europe, and China
  • •Direct sales and distributor channels support global reach
  • •Europe is important for manufacturing, sales, and cost structure
  • •China is both a sales market and a tariff exposure point
  • •Foreign currency exposure is material, especially euro and pound

Management is repositioning the company around translational medicine and NAMs, using its preclinical base to bridge in...

01
Build a translational medicine platformmedium-term

Positions the company for industry demand shifting toward NAMs and more human-relevant models.

02
Increase mix of consumables and softwaremedium-term

Raises recurring revenue and can improve margin stability versus one-time instrument sales.

03
Launch differentiated NPI productsshort-term

New platforms support growth and help defend pricing in specialized niches.

04
Improve operating efficiencyshort-term

Cost discipline is needed to support profitability in a soft demand environment.

The business is exposed to cyclical research spending, especially at academic institutions and CROs, and management has...

high

Softening demand from academic research institutions and CROs

These customers depend on grant and project funding, so purchases can be delayed when budgets tighten.

Scope
Revenue and order timing
Materiality
high
high

Tariffs and trade restrictions, especially between the U.S. and China

The company sells and sources internationally, so tariffs can raise costs and reduce demand.

Scope
Gross margin and supply chain
Materiality
high
high

Debt covenant and refinancing compliance

The company disclosed covenant waivers and refinancing milestone issues, which can limit financial flexibility.

Scope
Liquidity and capital structure
Materiality
high
high

Nasdaq minimum bid price noncompliance

Failure to regain compliance could lead to delisting and reduce access to capital and trading liquidity.

Scope
Capital markets access
Materiality
high
high

Goodwill and long-lived asset impairment

Weak demand and lower operating profits increase the chance that carrying values exceed fair value.

Scope
Balance sheet and earnings
Materiality
high
Revenue recognition and channel mix
Quarterly revenue comparability and gross margin
Goodwill and long-lived asset impairment
Non-cash operating expense and balance sheet carrying values
Foreign currency translation and transaction effects
Reported revenue, expenses, and comprehensive income
Debt refinancing and covenant accounting
Financing costs and going-concern/liquidity assessment

HARVARD BIOSCIENCE INC

HBIO · Laboratory Analytical Instruments

Epiroc B

EPI-A.ST · Industrials

New Wave

NEWA-B.ST · Consumer Discretionary

Duni

DUNI.ST · Consumer Staples

Hexatronic Group

HTRO.ST · Telecommunications

Apotea

APOTEA.ST · Consumer Staples

: 28.4.2026